OrbiMed is a healthcare investment firm managing approximately $17 billion across various funds, focusing on biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. The company invests globally, from early-stage private companies to large multinationals, and has over 130 professionals driving healthcare innovation.
- Biotechnology
- Pharmaceuticals
- Healthcare
- Life Sciences
- Cell Therapy
- Contract Development And Manufacturing Organization (Cdmo)
- Process Development
- Gmp Manufacturing
- Clinical Trials
- Commercialization Support
Leadership
| Name | Title | ||
|---|---|---|---|
| Carter Neild | Managing Partner |
in/carter-neild
|
|
| Managing Partner |
|
||
| Managing Partner |
|
|
|
| Partner |
|
|
|
| Partner |
|
|
|
| Partner |
|
||
| Partner |
|
|
|
| Partner |
|
|
Recent Transactions involving OrbiMed
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing |
Adaptive Phage Therapeutics |
BiomX |
Cystic Fibrosis FoundationAMR Action FundOrbiMedDeerfield Management CompanyNantahala Capital |
Biotechnology |
|
|
|
|
||
|
|
|
|
|
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →